A study published in Annals of Allergy, Asthma & Immunology found that dupilumab persistence was high after 1 year in adults with atopic dermatitis (AD).
In a retrospective cohort study, the authors reviewed data from the IBM MarketScan Commercial and Medicare database to characterize patients who initiated dupilumab and the therapy’s persistence. Adults with AD who initiated dupilumab (first dispensation = index date) between March 28, 2017, and March 31, 2018, were identified; these patients were followed up until September 30, 2018 or disenrollment. To characterize baseline treatment history and comorbidities, patients were required to have 12 months of regular preindex enrollment. Additionally, Kaplan-Meier analysis was used to determine dupilumab persistence at 6 and 12 months, with an assumption a frequent 14-day injection and a 30-day grace period.
Using the database, 1963 adults who initiated dupilumab (mean [SD] age 42.1 [15.7] years; 50.7% women; 49.8% with ≥1 atopic comorbidity) were identified. At baseline, AD therapies included topical corticosteroids (81.6%), systemic corticosteroids (72.5%), and systemic immunosuppressants (22.8%). At 6 and 12 months, dupilumab persistence was 91.9% (95% CI, 90.7%-93.2%) and 77.3% (95% CI, 75.0%-79.7%), respectively. Among the 329 patients who discontinued dupilumab, the risk of reinitiation was 78.8% (95% CI, 75.8%-81.7%) within an average of 4 months.
Following these results, the study determined that dupilumab persistence at 12 months was high, suggesting patient satisfaction with effectiveness, tolerability, and treatment regimen. —Jessica Garlewicz
Silverberg JI, Guttman-Yassky E, Gadkari A, et al. Real-world persistence with dupilumab among adults with atopic dermatitis. Ann Allergy Asthma Immunol. 2021;126(1):40-45. doi:10.1016/j.anai.2020.07.026